|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 241.41 CNY | -0.17% |
|
+3.12% | -5.99% |
| Nov. 19 | APT Medical Subsidiary Gets China Approval for Tumor Oxygen Starvation Particles Device | MT |
| Oct. 27 | APT Medical's Attributable Profit Jumps 6.8% in Q3 | MT |
| Capitalization | 34.04B 4.82B 4.14B 3.88B 3.61B 6.68B 433B 7.26B 45.35B 17.51B 205B 18.07B 17.69B 748B | P/E ratio 2025 * |
40.8x | P/E ratio 2026 * | 30.5x |
|---|---|---|---|---|---|
| Enterprise value | 32.95B 4.66B 4.01B 3.75B 3.5B 6.46B 420B 7.03B 43.9B 16.95B 198B 17.49B 17.12B 724B | EV / Sales 2025 * |
12.6x | EV / Sales 2026 * | 9.62x |
| Free-Float |
52.53% | Yield 2025 * |
0.61% | Yield 2026 * | 0.76% |
| 1 day | -0.17% | ||
| 1 week | +3.12% | ||
| Current month | +3.12% | ||
| 1 month | -16.85% | ||
| 3 months | -21.98% | ||
| 6 months | -10.70% | ||
| Current year | -5.99% |
| 1 week | 232.5 |  | 244.87 |
| 1 month | 231.61 | | 287.88 |
| Current year | 228.35 | | 337.2 |
| 1 year | 228.35 | | 337.2 |
| 3 years | 127.14 | | 337.2 |
| 5 years | 67.05 | | 337.2 |
| 10 years | 67.05 | | 337.2 |
| Manager | Title | Age | Since |
|---|---|---|---|
Zheng Hui Cheng
CEO | Chief Executive Officer | 61 | 2016-07-31 |
Zhen Hua Dai
DFI | Director of Finance/CFO | 57 | 2019-11-08 |
Yu Chen Qiu
CTO | Chief Tech/Sci/R&D Officer | 60 | 2010-12-31 |
| Director | Title | Age | Since |
|---|---|---|---|
Zheng Hui Cheng
CHM | Chairman | 61 | 2014-04-30 |
Yi Qing Xu
BRD | Director/Board Member | 62 | 2014-04-30 |
Zhen Hua Dai
BRD | Director/Board Member | 57 | 2013-06-30 |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.17% | +3.12% | -7.29% | +75.93% | 4.82B | |
| -0.01% | +0.01% | +0.01% | +37.71% | 12.57B | |
| +2.02% | +2.55% | +23.88% | +41.82% | 11.77B | |
| -0.41% | -0.53% | -16.36% | -0.61% | 7.61B | |
| +0.24% | -1.72% | +24.93% | -16.39% | 6.11B | |
| -0.03% | +4.60% | +14.22% | +22.64% | 5.23B | |
| -0.14% | +1.23% | +7.24% | +0.61% | 5.1B | |
| +0.05% | -.--% | +55.10% | +12.46% | 4.7B | |
| -1.00% | -5.18% | +52.99% | -16.68% | 2.01B | |
| +1.23% | -0.82% | +3.18% | -49.72% | 1.62B | |
| Average | +0.18% | -0.17% | +15.79% | +10.78% | 6.15B | |
| Weighted average by Cap. | +0.33% | +0.42% | +12.28% | +21.01% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 2.62B 370M 318M 298M 278M 513M 33.31B 558M 3.49B 1.35B 15.73B 1.39B 1.36B 57.53B | 3.4B 481M 413M 387M 361M 666M 43.25B 725M 4.53B 1.75B 20.43B 1.8B 1.77B 74.68B |
| Net income | 834M 118M 101M 95.01M 88.56M 164M 10.62B 178M 1.11B 429M 5.02B 443M 433M 18.34B | 1.12B 158M 136M 128M 119M 220M 14.26B 239M 1.49B 576M 6.73B 595M 582M 24.62B |
| Net Debt | -1.09B -154M -132M -124M -115M -213M -13.84B -232M -1.45B -559M -6.54B -577M -565M -23.91B | -1.38B -195M -167M -157M -146M -270M -17.52B -294M -1.83B -708M -8.27B -731M -715M -30.25B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 25-12-05 | 241.41 ¥ | -0.17% | 852,790 |
| 25-12-04 | 241.82 ¥ | +0.17% | 987,042 |
| 25-12-03 | 241.40 ¥ | -0.22% | 963,082 |
| 25-12-02 | 241.94 ¥ | +0.21% | 1,353,224 |
| 25-12-01 | 241.43 ¥ | +3.13% | 1,800,599 |
End-of-day quote Shanghai S.E., December 04, 2025
More quotes
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Annual profits - Rate of surprise
- Stock Market
- Equities
- 688617 Stock
Select your edition
All financial news and data tailored to specific country editions
